Dulaglutide, marketed under the brand name Trulicity, is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA) approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus. It is also approved to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Dulaglutide is administered as a subcutaneous injection once weekly. Its primary actions include stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon secretion, slowing gastric emptying, and promoting a feeling of fullness, which can lead to reduced food intake. These combined effects contribute to improved glycemic control and can also support weight management. As an injectable medication, it is typically prescribed by a healthcare professional familiar with diabetes management. (FDA label, DrugBank)
Deep dive
Tap a section to expand.
Known interactions
Category rule: glp1 × supplement
Note
GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.
Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Frequently asked
Sources referenced
["U.S. Food and Drug Administration (FDA) label for Trulicity", "DrugBank", "PubChem", "Mayo Clinic", "Cochrane Library"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the glp1 category or studied for the same goals.
